Compare Illumina, Inc. (ILMN) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs RLX Technology Inc — how do they compare? Illumina, Inc. trades at $180.13 (market cap $27.94B), while RLX Technology Inc trades at $2.06 (market cap $2.52B). The key difference: Illumina, Inc. is far larger — about 11.1× RLX Technology Inc's market cap, and RLX Technology Inc pays a 4.85% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | RLX | |
|---|---|---|
Market Cap | $27.94B | $2.52B |
Sector | Health | Technology |
52-Week High | $194.33 | $2.73 |
52-Week Low | $91.00 | $1.79 |
Enterprise Value | $29.33B | $1.15B |
Dividend Yield | — | 4.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
RLX trades at $2.06, up 0.49% today, with a bullish technical signal from moving averages but bearish oscillators. The company reported Q1 2026 revenue growth driven by international expansion, with 2025 revenue of $3.62B and net income of $921.87M. Recent news highlights the vaping industry's projected growth and RLX's cash-rich, debt-free balance sheet.
Outlook is mixed: strong fundamentals and industry tailwinds support growth, but recent EPS misses and a single analyst 'Hold' rating suggest caution. Key risks include regulatory scrutiny and execution challenges in global markets. The stock presents opportunity for long-term investors if expansion succeeds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
